U.S. Tariff Probe on Germany Drug Pricing Policies Launched

AI Summary

The U.S. has initiated an investigation under Section 301 of the Trade Act into Germany's pharmaceutical pricing, citing 'persistent underpayment' for medicines. This probe raises concerns regarding Germany's legislation aimed at controlling drug costs, which may lead to potential tariffs. U.S. Trade Representative Jamieson Greer emphasized the need for fair contributions to global pharmaceutical research. Germany's proposed health insurance overhaul includes measures that may discourage the introduction of new drugs, impacting companies in the pharmaceutical sector. The outcome of this investigation could influence future U.S.-Germany trade relations and pricing policies for medications.